Cue Biopharma surges after positive results from mid-stage study for CUE-221

Cue Biopharma

21/09/2026 10:25

** Cue Biopharma CUE.O shares soar 28.9% to $47.74 in premarket trading
** Co announces positive results from mid-stage study for CUE-221 in hives treatment
** Says phase 2 primary and key secondary endpoints met
** CUE's Q2 revenue more than doubled earlier this month
** Up to last day's close, shares up more than 300% YTD

 (Reporting by Sudeshna Ghoshal in Bengaluru)
 ((Sudeshna.Ghoshal@thomsonreuters.com;))